Peptide-Drug Conjugate Development & Characterization

Q: Can you work with client‑supplied PDC candidates?

Yes. Client‑supplied PDCs can be scoped for identity confirmation, chromatographic profiling, related‑species analysis, conjugation‑site evidence, stability, payload release, or comparative candidate studies. The analytical plan is defined from the construct chemistry and the development question.

Q: Can the project include PDC design or conjugate generation?

Project scope can include design review and project‑specific conjugate generation when the required peptide, linker, payload, and chemistry are compatible with the available workflow. Exact synthetic route, scale, purification strategy, and material requirements are confirmed during scoping rather than assumed from a fixed catalog process.

Q: How is the conjugation site confirmed?

Confirmation can combine intact‑mass evidence, chromatographic behavior, known conjugation chemistry, and MS/MS of modified peptide species when fragmentation provides site‑informative ions. Not every payload‑linker combination fragments cleanly enough for residue‑level localization, so the confidence level is reported according to the available evidence.

Q: Which stability conditions can be evaluated?

Studies can be designed around project‑appropriate buffers, plasma or serum, enzymes, reducing conditions, pH, or other mechanistic triggers. The exact matrix, temperature, duration, and time points depend on the intended PDC mechanism and the decision the study must support.

Peptide-Drug Conjugate Development and Analytical Strategy

A peptide-drug conjugate (PDC) is not simply a peptide with a payload attached. The targeting or functional peptide, conjugation site, linker, payload, and overall physicochemical properties interact as a single construct. A change that improves one element can weaken another: conjugation can alter peptide binding or conformation, a stable linker can delay payload release, and a hydrophobic payload can change solubility, retention behavior, nonspecific binding, or clearance.

Our PDC development and characterization service is designed for research teams moving from a peptide concept, conjugation plan, or early PDC candidate toward analytically defined constructs. Programs may enter with a known targeting peptide, a peptide lead emerging from discovery or screening, or an existing conjugate that requires characterization or troubleshooting. Depending on project stage, peptide-drug conjugation can be integrated with purification, LC-MS characterization, and stability or release studies, or the project can begin with client-supplied PDCs. The analytical plan is built around the development decision: confirm what molecular species were produced, determine how the peptide-linker-payload construct changes under relevant conditions, and compare candidates using evidence that supports the next research step.

This page sits within our Peptidomics-Based Drug Discovery portfolio. It focuses on peptide-drug conjugates rather than general peptide synthesis, manufacturing, or regulatory CMC release testing.

PDC Design: Peptide, Conjugation Site, Linker, and Payload

Most PDC programs require coordinated decisions across four design variables. The optimal combination depends on the biological target, required intracellular or extracellular release mechanism, payload properties, and the analytical behavior of the complete construct.

Peptide Ligand and Conjugation Site

Define the targeting or functional peptide, sequence modifications, linear or constrained scaffold where applicable, and an attachment site that preserves the intended peptide function while enabling a chemically interpretable conjugate.

Linker and Release Mechanism

Select a cleavable or non-cleavable linker according to the required stability and release behavior. Enzyme-responsive, redox-sensitive, pH-responsive, or other trigger concepts should be evaluated against the actual matrix and mechanism rather than assumed from linker class alone.

Payload Compatibility

Assess whether payload size, hydrophobicity, charge, functional groups, and attachment chemistry are compatible with the peptide and linker. The conjugated construct can behave differently from the unconjugated payload in chromatography, solubility, stability, and biological exposure.

Construct Format and Controls

Plan the intended stoichiometry, site-specificity, peptide and payload controls, linker intermediates where useful, and the analytical comparisons needed to distinguish intact PDC from unconjugated or degraded species.

PDC Characterization by LC-MS and LC-MS/MS

Analytical characterization should establish the molecular identity of the conjugate before biological or stability data are interpreted. For PDCs, an expected nominal mass alone is not sufficient when incomplete conjugation, alternative attachment sites, residual unconjugated peptide, free payload, side products, oxidation, truncation, or linker-derived species may be present.

Intact Conjugate Identity

Use intact-mass and chromatographic evidence to determine whether the observed major species is consistent with the intended peptide-linker-payload construct.

Conjugation-Site Evidence

Where fragmentation behavior and construct design permit, MS/MS can support localization of the modified residue or distinguish intended site-specific attachment from alternative conjugation products.

Conjugate Homogeneity

Evaluate the distribution of intact conjugate and related species rather than borrowing antibody-drug-conjugate metrics such as DAR when the PDC has a defined peptide-to-payload stoichiometry.

Unconjugated and Related Species

Track residual peptide, payload-related species, linker intermediates, hydrolysis products, or other project-relevant impurities that can confound downstream stability or activity readouts.

Peptide Sequence Integrity

Review truncation, oxidation, deamidation, terminal processing, or other peptide changes when they are relevant to candidate identity, stability, or target recognition.

Comparative Candidate Profiling

Apply the same analytical framework across related constructs so that differences in linker, conjugation site, payload, or peptide modification can be interpreted consistently.

Linker Stability, Deconjugation, and Payload Release

A central PDC development question is whether the conjugate remains intact under the conditions where stability is required and releases the payload when the intended trigger is encountered. Loss of intact PDC signal alone does not identify the mechanism. A more informative study follows the intact conjugate together with released or transformed species.

Analytical Species	What It Can Indicate	Interpretation Considerations
Intact PDC	Persistence of the complete peptide-linker-payload construct over time or across test conditions.	A decrease can reflect linker cleavage, peptide degradation, adsorption, precipitation, or another transformation; mechanism requires supporting species-level evidence.
Released Payload	Payload liberation under spontaneous, matrix-driven, or trigger-specific conditions.	Quantitation strategy depends on payload chemistry, matrix, calibration approach, and whether free payload is stable after release.
Peptide or Peptide-Linker Fragments	Proteolysis, linker cleavage, or catabolic processing of the carrier portion.	Fragment mapping helps distinguish peptide degradation from true payload deconjugation.
Other PDC-Related Species	Oxidation, hydrolysis, adduct formation, rearrangement, or other project-specific transformations.	Identification confidence depends on chromatographic behavior, accurate mass, fragmentation evidence, and availability of relevant controls or standards.

Stability and release experiments can be configured for project-appropriate buffers, biological matrices, enzymes, reducing conditions, pH ranges, or other mechanistic triggers. Conditions and time points are defined during scoping rather than treated as a universal PDC protocol.

Common PDC Development Projects

PDC projects often begin with a specific design uncertainty or an unexpected analytical result rather than with a generic request for "PDC development." The study can be organized around the variable that must be resolved before the next candidate-selection decision.

Project Scenario	Typical Starting Point	Decision Supported
Linker Comparison	Related PDCs that share the peptide and payload but differ in linker chemistry or release trigger.	Determines which design provides the most appropriate balance between construct stability and intended payload release under the study conditions.
Conjugation-Site Comparison	The same peptide-linker-payload concept attached through alternative residues or reactive handles.	Tests whether attachment position changes product profile, stability, or the peptide-related function that matters for the project.
Payload Comparison	Matched constructs in which peptide and linker are controlled while payload chemistry is varied.	Shows how payload choice changes chromatographic behavior, related species, stability, release behavior, or downstream assay performance.
Matrix Stability and Release	A selected PDC exposed to project-relevant buffer, biological matrix, enzyme system, or mechanistic trigger.	Distinguishes peptide degradation, linker cleavage, deconjugation, and payload release instead of treating loss of intact PDC as a single mechanism.
PDC Failure Investigation	An existing construct with unexpected instability, extra chromatographic peaks, premature payload appearance, or loss of intended activity.	Helps determine whether the problem is associated with peptide degradation, linker transformation, payload instability, alternative conjugation products, or another construct-specific species.

When target engagement, cell uptake, internalization, or activity is central to candidate selection, project-specific functional follow-up can be interpreted alongside the analytical data where appropriate. A chemically correct PDC does not by itself demonstrate preserved peptide function, so matched unconjugated-peptide, PDC, and free-payload controls are considered when they help isolate the effect of conjugation.

PDC Candidate Comparison and Control Strategy

Well-chosen controls make PDC data easier to interpret because they separate effects of conjugation from effects of the peptide, linker, or payload alone. The exact control set depends on the project, but the following comparisons are often informative.

Control or Comparator	Primary Purpose	Example Question
Unconjugated Peptide	Separates peptide behavior from effects introduced by linker or payload attachment.	Did conjugation alter retention, stability, or target-related performance?
Free Payload	Distinguishes conjugate-associated behavior from payload behavior after release.	Is observed payload signal caused by intended release, nonspecific hydrolysis, or carryover from unconjugated material?
Linker or Peptide-Linker Intermediate	Provides a reference for linker-related transformations where the intermediate is available and analytically informative.	Which degradation products originate from the linker rather than the peptide or payload?
Alternative PDC Candidate	Supports head-to-head comparison of peptide sequence, conjugation site, linker, or payload design.	Which construct provides the best balance of identity, stability, controlled release, and downstream assay performance?

PDC Development Workflow

Project & Construct Review

Define peptide, target, attachment site, linker, payload, controls, and development question

PDC Generation or Sample Intake

Receive client material or establish a project-specific conjugate preparation route

Identity & Conjugation Characterization

Confirm intact construct, chromatographic profile, attachment evidence, and related species

Stability, Release & Bioanalysis

Track intact PDC, released payload, peptide fragments, and transformation products

Candidate Comparison & Reporting

Integrate analytical evidence and rank constructs for the next research stage

Project and Construct Review

The study begins with the intended biological target or delivery concept, peptide sequence and modifications, conjugation handle, linker class, payload chemistry, available controls, and the decision the data must support. Existing constructs can be reviewed directly, while early concepts can be scoped around the analytical questions that will determine whether a PDC candidate is worth advancing.

PDC Generation or Sample Intake

Client-supplied conjugates can enter directly into characterization. When project scope includes conjugate generation, the peptide, linker, payload, attachment chemistry, protecting-group requirements, purification strategy, and reference controls are aligned before analytical confirmation. Exact chemistry and scale remain project-dependent.

Identity and Conjugation Characterization

Chromatographic and mass-spectrometric evidence is used to assess the intended intact PDC, related species, unconjugated components, and conjugation-site evidence where technically feasible. This stage establishes the molecular basis for subsequent stability, release, and biological interpretation.

Stability, Release, and Bioanalytical Follow-Up

The selected PDC is evaluated under project-appropriate stability or trigger conditions. Intact conjugate, released payload, peptide-derived fragments, and other transformation products can be followed as separate analytical species. When broader PK, metabolic stability, or ADME questions become primary, the project can transition to our Therapeutic Peptide Bioanalysis or Peptide DMPK and ADME workflows.

Candidate Comparison and Reporting

Analytical results are integrated across identity, conjugate homogeneity, stability, release behavior, related species, and any project-specific functional or bioanalytical readouts. The final report distinguishes measured evidence from mechanistic interpretation and identifies unresolved risks that should be addressed before further development.

PDC Candidate Selection and Development Decisions

PDC characterization should follow the development question rather than a fixed list of assays. The same construct may require different evidence during design selection, stability optimization, and later bioanalytical work.

Development Question	Primary Analytical Readout	Decision Supported
Was the intended PDC produced?	Intact mass, chromatographic profile, related-species review, and attachment evidence where feasible.	Confirms whether downstream testing is being performed on the intended molecular construct.
Is the conjugate stable enough for the intended experiment?	Time-resolved intact PDC together with released payload and peptide/linker-derived products.	Identifies premature cleavage, peptide degradation, or other loss pathways that can confound biological interpretation.
Does the linker release the payload under the intended condition?	Trigger-dependent payload release and transformation-product profiling.	Tests whether linker behavior matches the proposed release mechanism rather than relying on linker classification alone.
Does conjugation preserve the intended peptide function?	Project-specific binding, internalization, or activity readout interpreted alongside matched peptide and PDC controls.	Distinguishes a chemically correct conjugate from a construct in which attachment has compromised target engagement or functional delivery.
Which candidate should advance?	Comparable identity, stability, release, and project-specific functional or bioanalytical metrics across constructs.	Supports evidence-based selection among peptide, site, linker, or payload variants.

Projects whose primary goal is routine release-style testing of a peptide drug substance rather than PDC discovery should be routed to our Peptide Drug Quality Control service instead.

Information Needed to Start a PDC Project

A useful PDC inquiry does not require a completed protocol, but it should define the molecular components, current project stage, and the decision the study needs to support. The information below allows the analytical route to be scoped around the actual construct rather than a fixed assay package.

Project Information	What to Provide	Why It Matters
Peptide	Sequence or molecular description, linear or cyclic format, terminal groups, noncanonical residues, and other known modifications.	Defines molecular identity, available conjugation handles, expected MS behavior, and possible stability liabilities.
Payload	Payload identity or structure, approximate molecular properties, available functional group, and reference material if available.	Guides conjugation compatibility, chromatographic strategy, released-payload analysis, and interpretation of transformed species.
Conjugation Design	Proposed or known attachment site, reactive handle, linker structure or class, and intended release mechanism.	Determines which attachment, stability, and release questions can be tested analytically.
Project Stage	Concept stage, components in hand, purified PDC, candidate panel, or an existing construct requiring troubleshooting.	Determines whether the project should begin with design review, conjugation support, characterization, comparison, or failure investigation.
Study Objective	Identity confirmation, conjugation-site evidence, linker comparison, stability, payload release, degradation mapping, or candidate ranking.	Keeps the analytical package focused on the decision that will advance or deprioritize the construct.
Material and Test Matrix	Available material, concentration if known, solvent or formulation, biological matrix or trigger condition, and relevant storage history.	Supports realistic method selection and helps identify matrix, solubility, adsorption, or stability constraints before testing begins.

To scope a PDC project efficiently, send the peptide sequence or molecular description, payload and linker information, material status, proposed attachment chemistry if known, test matrix or trigger condition, and the decision you need the study to support. If some design elements are still open, identify the variables you want compared so the project can be built around those choices.

Representative Results

The visualizations below illustrate analytical outputs that can support peptide-drug conjugate development. They are representative reporting formats, not data from a specific customer project.

Intact PDC Identity and Chromatographic Profile

Representative LC-MS characterization of intact peptide-drug conjugate identity and chromatographic profile

Conjugation-Site Evidence

Representative MS/MS evidence supporting the intended peptide-drug conjugate attachment site

PDC Stability and Payload Release

Representative time-resolved peptide-drug conjugate stability and payload release profile

PDC Degradation and Catabolite Map

Representative LC-MS/MS map of peptide-drug conjugate degradation products and catabolites

Representative outputs are illustrative. Final analyses depend on PDC structure, linker chemistry, payload, sample matrix, standards, and data quality.

Typical Deliverables

Project deliverables are defined during scoping and may include:

PDC Design and Analytical Strategy Summary
A structured review of peptide, conjugation site, linker, payload, controls, and the recommended analytical questions for the project.
Conjugate Identity and Related-Species Dataset
Chromatographic and mass-spectrometric evidence for the intended PDC together with observed unconjugated, partially transformed, or other project-relevant species.
Conjugation-Site or Stoichiometry Evidence
Project-appropriate evidence supporting the intended attachment pattern where the chemistry and fragmentation behavior permit confident interpretation.
Stability and Payload-Release Results
Time- or condition-dependent measurements of intact PDC, released payload, peptide/linker fragments, and other selected transformation products.
Degradation or Biotransformation Map
Annotated pathways for observed PDC-related species when sufficient chromatographic and MS/MS evidence is available.
Comparative Candidate Summary
Side-by-side assessment of constructs differing in peptide, attachment site, linker, payload, or another controlled design variable.
Analytical Report and Data Package
A structured report containing methods, QC, representative chromatograms or spectra, interpretation notes, and project-specific processed or raw data files.

References

Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem. 2020;8:571. https://doi.org/10.3389/fchem.2020.00571
Gong L, Zhao H, Liu Y, et al. Research advances in peptide-drug conjugates. Acta Pharm Sin B. 2023;13(9):3659-3677. https://doi.org/10.1016/j.apsb.2023.02.013
Dean TT, Jelu-Reyes J, Allen AC, Moore TW. Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics. J Med Chem. 2024;67(3):1641-1661. https://doi.org/10.1021/acs.jmedchem.3c01835
Rizvi SFA, Zhang L, Zhang H, Fang Q. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic. ACS Pharmacol Transl Sci. 2024;7(2):309-334. https://doi.org/10.1021/acsptsci.3c00269
Armstrong A, Coburn F, Nsereko Y, Al Musaimi O. Peptide-Drug Conjugates: A New Hope for Cancer. J Pept Sci. 2025;31(8):e70040. https://doi.org/10.1002/psc.70040
Kumar A, Sharma R, Yadav AK. Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges. Adv Drug Deliv Rev. 2026;239:115960. https://doi.org/10.1016/j.addr.2026.115960

For research use only. Not for use in diagnostic or therapeutic procedures.

FAQ for PDC Development and Characterization

What information should I provide to scope a PDC project? +

Provide the peptide sequence or molecular form, payload and linker information, intended or known attachment site, current project stage, available material, test matrix or trigger condition, and the decision the study needs to support. If some elements are still undecided, indicate the variables you want compared so the analytical plan can be built around those choices.

Can you work with client-supplied PDC candidates? +

Yes. Client-supplied PDCs can be scoped for identity confirmation, chromatographic profiling, related-species analysis, conjugation-site evidence, stability, payload release, or comparative candidate studies. The analytical plan is defined from the construct chemistry and the development question.

Can the project include PDC design or conjugate generation? +

Project scope can include design review and project-specific conjugate generation when the required peptide, linker, payload, and chemistry are compatible with the available workflow. Exact synthetic route, scale, purification strategy, and material requirements are confirmed during scoping rather than assumed from a fixed catalog process.

How do cleavable and non-cleavable linkers differ in PDC development? +

Cleavable linkers are designed to release the payload in response to a defined chemical or biological trigger, whereas non-cleavable linkers rely on a different release mechanism, often involving breakdown of the carrier portion. The correct choice depends on the biological route, required stability, payload chemistry, and whether the proposed trigger operates under the intended experimental conditions.

How is the conjugation site confirmed? +

Confirmation can combine intact-mass evidence, chromatographic behavior, known conjugation chemistry, and MS/MS of modified peptide species when fragmentation provides site-informative ions. Not every payload-linker combination fragments cleanly enough for residue-level localization, so the confidence level is reported according to the available evidence.

Do PDCs use a drug-to-carrier ratio like ADCs? +

Many PDCs are designed as chemically defined small conjugates with a specified peptide-to-payload stoichiometry, so ADC-style drug-to-antibody ratio terminology is often not the most informative description. We instead report the intended construct, observed related species, and stoichiometric or site-specific evidence appropriate to the PDC design.

Can intact PDC, free peptide, and released payload be distinguished in the same study? +

They can often be followed as separate analytical species when the chemistry, chromatography, ionization, and available standards support that design. In complex matrices, separate sample-preparation or quantitative methods may be needed for the intact conjugate and released payload.

Which stability conditions can be evaluated? +

Studies can be designed around project-appropriate buffers, plasma or serum, enzymes, reducing conditions, pH, or other mechanistic triggers. The exact matrix, temperature, duration, and time points depend on the intended PDC mechanism and the decision the study must support.

Can PDC degradation products and catabolites be identified? +

Yes, when the species are detectable and generate sufficient chromatographic and mass-spectrometric evidence. Analysis may distinguish peptide cleavage, linker transformation, deconjugation, payload release, and other PDC-related products. Structural assignments are reported with an evidence level appropriate to the available MS/MS and reference information.

Can cyclic or otherwise modified peptides be used in PDC projects? +

Potentially. Cyclization, terminal modification, lipidation, PEG-related elements, noncanonical residues, or other peptide modifications can change conjugation chemistry, mass-spectrometric behavior, stability, and bioanalysis. Compatibility is therefore reviewed at the construct level before the analytical or synthetic workflow is finalized.

How much PDC material is required? +

Material requirements are project-dependent and vary with the number of constructs, analytical methods, matrices, time points, replicates, standards, and whether functional or bioanalytical follow-up is included. A practical input requirement is defined after the study design is reviewed.